{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:51:14Z","timestamp":1790412674118,"version":"4.1.0"},"reference-count":149,"publisher":"European Respiratory Society (ERS)","issue":"153","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,8,23]]},"published-print":{"date-parts":[[2019,9,30]]},"abstract":"<jats:p>Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely observed (&lt;5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (NSCLC) than in those with other cancers. Likewise, it is more common in those receiving programmed cell death (PD)-1\/PD-1 ligand inhibitors rather than cytotoxic T-lymphocyte antigen (CTLA)-4 inhibitors alone. The frequency of ICI-P is higher when anti-PD-1 and anti-CTLA-4 are administered concomitantly. Despite the low fatality rate (\u224813%), ICI-P is the leading cause of ICI-related deaths. This narrative review focuses on the epidemiology, clinical and radiological presentation and prognosis of ICI-P occurring in patients, especially those with advanced NSCLC. Emphasis is placed on the differences in terms of frequency or clinical picture observed depending on whether the ICI is used as monotherapy or in combination with another ICI or chemotherapy. Other pulmonary complications observed in cancer patients, yet not necessarily immune-related, are reviewed, such as sarcoid-like granulomatosis, tuberculosis or other infections. A proposal for pragmatic management, including differential diagnosis and therapeutic strategies, is presented, based on the ICI-P series reported in the literature and published guidelines.<\/jats:p>","DOI":"10.1183\/16000617.0058-2019","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T10:59:07Z","timestamp":1570618747000},"page":"190058","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":93,"title":["Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer"],"prefix":"10.1183","volume":"28","author":[{"given":"Jacques","family":"Cadranel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Canellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-8961","authenticated-orcid":false,"given":"Lise","family":"Matton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Darrason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Parrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-3228","authenticated-orcid":false,"given":"Jean-Marc","family":"Naccache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armelle","family":"Lavol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-6951","authenticated-orcid":false,"given":"Vincent","family":"Fallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2019,10,9]]},"reference":[{"key":"2024102403404831000_28.153.190058.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1187"},{"key":"2024102403404831000_28.153.190058.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02072-2017"},{"key":"2024102403404831000_28.153.190058.3","doi-asserted-by":"crossref","unstructured":"Berghmans T , Evison M , Blum TG , et al. New drugs in thoracic oncology: needs and knowledge \u2013 an online ERS Lung Cancer Assembly survey. ERJ Open Res 2018; 4: 00040\u20132018.","DOI":"10.1183\/23120541.00040-2018"},{"key":"2024102403404831000_28.153.190058.4","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"2024102403404831000_28.153.190058.5","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"2024102403404831000_28.153.190058.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2024102403404831000_28.153.190058.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2024102403404831000_28.153.190058.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"2024102403404831000_28.153.190058.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2024102403404831000_28.153.190058.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2024102403404831000_28.153.190058.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2024102403404831000_28.153.190058.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2024102403404831000_28.153.190058.13","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403404831000_28.153.190058.14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403404831000_28.153.190058.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2024102403404831000_28.153.190058.16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403404831000_28.153.190058.17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"2024102403404831000_28.153.190058.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"2024102403404831000_28.153.190058.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2024102403404831000_28.153.190058.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2024102403404831000_28.153.190058.21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"2024102403404831000_28.153.190058.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226"},{"issue":"Suppl. 4","key":"2024102403404831000_28.153.190058.23","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403404831000_28.153.190058.24","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2024102403404831000_28.153.190058.25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2024102403404831000_28.153.190058.26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2024102403404831000_28.153.190058.27","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.lungcan.2017.08.020","article-title":"Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy","volume":"113","author":"Hochmair","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403404831000_28.153.190058.28","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2024102403404831000_28.153.190058.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2024102403404831000_28.153.190058.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2024102403404831000_28.153.190058.31","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024102403404831000_28.153.190058.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"2024102403404831000_28.153.190058.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2024102403404831000_28.153.190058.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"2024102403404831000_28.153.190058.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30231-0"},{"key":"2024102403404831000_28.153.190058.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2024102403404831000_28.153.190058.37","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"2024102403404831000_28.153.190058.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2024102403404831000_28.153.190058.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"2024102403404831000_28.153.190058.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"},{"key":"2024102403404831000_28.153.190058.41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615"},{"key":"2024102403404831000_28.153.190058.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"2024102403404831000_28.153.190058.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"key":"2024102403404831000_28.153.190058.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2024102403404831000_28.153.190058.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5"},{"key":"2024102403404831000_28.153.190058.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2024102403404831000_28.153.190058.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"2024102403404831000_28.153.190058.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"2024102403404831000_28.153.190058.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683"},{"key":"2024102403404831000_28.153.190058.50","doi-asserted-by":"crossref","first-page":"8910","DOI":"10.18632\/oncotarget.13315","article-title":"Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Costa","year":"2017","journal-title":"Oncotarget"},{"key":"2024102403404831000_28.153.190058.51","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0237"},{"key":"2024102403404831000_28.153.190058.52","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx286"},{"key":"2024102403404831000_28.153.190058.53","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024102403404831000_28.153.190058.54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front Pharmacol"},{"key":"2024102403404831000_28.153.190058.55","doi-asserted-by":"publisher","DOI":"10.1177\/1753465816636557"},{"key":"2024102403404831000_28.153.190058.56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"2024102403404831000_28.153.190058.57","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"2024102403404831000_28.153.190058.58","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","article-title":"The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"2024102403404831000_28.153.190058.59","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl Lung Cancer Res"},{"key":"2024102403404831000_28.153.190058.60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2019.00108","article-title":"Risk of pneumonitis and pneumonia associated with immune checkpoint inhibitors for solid tumors: a systematic review and meta-analysis","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"2024102403404831000_28.153.190058.61","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1467"},{"key":"2024102403404831000_28.153.190058.62","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1179\/2295333715Y.0000000047","article-title":"Unusual pulmonary toxicity of ipilimumab treated by macrolides","volume":"70","author":"Mailleux","year":"2015","journal-title":"Acta Clin Belg"},{"key":"2024102403404831000_28.153.190058.63","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1097\/RLU.0000000000001673","article-title":"Ipilimumab-induced organizing pneumonia on 18F-FDG PET\/CT in a patient with malignant melanoma","volume":"42","author":"Raad","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2024102403404831000_28.153.190058.64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/1346-8138.13810","article-title":"Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy","volume":"44","author":"Nomura","year":"2017","journal-title":"J Dermatol"},{"key":"2024102403404831000_28.153.190058.65","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2016.69.9793","article-title":"Pulmonary infiltrates in a patient with advanced melanoma","volume":"35","author":"Powell","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024102403404831000_28.153.190058.66","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv199"},{"key":"2024102403404831000_28.153.190058.67","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2169\/internalmedicine.8271-16","article-title":"Nivolumab-induced acute fibrinous and organizing pneumonia (AFOP)","volume":"56","author":"Ishiwata","year":"2017","journal-title":"Intern Med"},{"key":"2024102403404831000_28.153.190058.68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12890-018-0592-x","article-title":"High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review","volume":"18","author":"Koyama","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024102403404831000_28.153.190058.69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2017.07.049","article-title":"Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer","volume":"85","author":"Mahjoubi","year":"2017","journal-title":"Eur J Cancer"},{"key":"2024102403404831000_28.153.190058.70","doi-asserted-by":"crossref","first-page":"33043","DOI":"10.18632\/oncotarget.25984","article-title":"Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma","volume":"9","author":"Teixidor","year":"2018","journal-title":"Oncotarget"},{"key":"2024102403404831000_28.153.190058.71","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.lungcan.2016.07.010","article-title":"Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma","volume":"99","author":"Gounant","year":"2016","journal-title":"Lung Cancer"},{"key":"2024102403404831000_28.153.190058.72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0267"},{"key":"2024102403404831000_28.153.190058.73","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjh.14441","article-title":"PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy","volume":"180","author":"Nishino","year":"2018","journal-title":"Br J Haematol"},{"key":"2024102403404831000_28.153.190058.74","first-page":"17","article-title":"Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure \u2013 a review with case series","volume":"26","author":"Akella","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"2024102403404831000_28.153.190058.75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0160221"},{"key":"2024102403404831000_28.153.190058.76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2024102403404831000_28.153.190058.77","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.12.016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403404831000_28.153.190058.79","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2018.09.015","article-title":"Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"125","author":"Cho","year":"2018","journal-title":"Lung Cancer"},{"key":"2024102403404831000_28.153.190058.80","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017"},{"key":"2024102403404831000_28.153.190058.81","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/annonc\/mdx214","article-title":"Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment","volume":"28","author":"Yanagihara","year":"2017","journal-title":"Ann Oncol"},{"key":"2024102403404831000_28.153.190058.82","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/1759-7714.12853","article-title":"Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis","volume":"9","author":"Ide","year":"2018","journal-title":"Thorac Cancer"},{"key":"2024102403404831000_28.153.190058.83","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2024102403404831000_28.153.190058.84","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00262-017-2071-2","article-title":"Ipilimumab and early signs of pulmonary toxicity in patients with metastastic melanoma: a prospective observational study","volume":"67","author":"Franzen","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2024102403404831000_28.153.190058.85","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jtho.2018.12.017","article-title":"Checkpoint inhibitor pneumonitis: too clinically serious for benefit?","volume":"14","author":"Le","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.86","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292"},{"key":"2024102403404831000_28.153.190058.87","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijrobp.2017.02.003","article-title":"Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy","volume":"98","author":"Bang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024102403404831000_28.153.190058.88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.radonc.2017.06.006","article-title":"Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation","volume":"124","author":"Pike","year":"2017","journal-title":"Radiother Oncol"},{"key":"2024102403404831000_28.153.190058.89","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/CMR.0000000000000386","article-title":"Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination","volume":"27","author":"Aboudaram","year":"2017","journal-title":"Melanoma Res"},{"key":"2024102403404831000_28.153.190058.90","doi-asserted-by":"crossref","first-page":"e1214788","DOI":"10.1080\/2162402X.2016.1214788","article-title":"Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma","volume":"5","author":"Liniker","year":"2016","journal-title":"Oncoimmunology"},{"key":"2024102403404831000_28.153.190058.91","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw417"},{"key":"2024102403404831000_28.153.190058.92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx408"},{"key":"2024102403404831000_28.153.190058.93","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0082"},{"key":"2024102403404831000_28.153.190058.94","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamadermatol.2017.2222","article-title":"Clinical outcomes of metastatic melanoma treated with checkpoint inhibitors and multisite radiotherapy","volume":"153","author":"Doyen","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2024102403404831000_28.153.190058.95","doi-asserted-by":"crossref","unstructured":"Fiorica F , Belluomini L , Stefanelli A , et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination. Am J Clin Oncol 2018. In press doi: 10.1097\/COC.0000000000000428.","DOI":"10.1097\/COC.0000000000000428"},{"key":"2024102403404831000_28.153.190058.96","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1002\/cam4.1825","article-title":"Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC","volume":"7","author":"Lesueur","year":"2018","journal-title":"Cancer Med"},{"key":"2024102403404831000_28.153.190058.97","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jtho.2018.01.012","article-title":"Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer","volume":"13","author":"Hubbeling","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.98","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","article-title":"Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial","volume":"18","author":"Shaverdian","year":"2017","journal-title":"Lancet Oncol"},{"key":"2024102403404831000_28.153.190058.99","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamaoncol.2017.3808","article-title":"Clinical outcomes in patients with metastatic lung cancer treated with PD-1\/PD-L1 inhibitors and thoracic radiotherapy","volume":"4","author":"Hwang","year":"2018","journal-title":"JAMA Oncol"},{"key":"2024102403404831000_28.153.190058.100","first-page":"5199","article-title":"Correlation of radiation pneumonitis history before nivolumab with onset of interstitial lung disease and progression-free survival of patients with pre-treated advanced non-small cell lung cancer","volume":"37","author":"Tamiya","year":"2017","journal-title":"Anticancer Res"},{"key":"2024102403404831000_28.153.190058.101","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx115"},{"key":"2024102403404831000_28.153.190058.102","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01737-2017"},{"key":"2024102403404831000_28.153.190058.103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"2024102403404831000_28.153.190058.104","doi-asserted-by":"crossref","first-page":"S370","DOI":"10.1016\/j.jtho.2018.08.350","article-title":"MA05.02 PACIFIC subgroup analysis: pneumonitis in stage III, unresectable NSCLC patients treated with durvalumab vs. placebo after CRT","volume":"13","author":"Vansteenkiste","year":"2018","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.105","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.21037\/jtd.2018.05.75","article-title":"Lung cancer and interstitial lung disease: a literature review","volume":"10","author":"Naccache","year":"2018","journal-title":"J Thorac Dis"},{"key":"2024102403404831000_28.153.190058.106","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S2213-2600(17)30478-2","article-title":"Patients with IPF and lung cancer: diagnosis and management","volume":"6","author":"Tzouvelekis","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403404831000_28.153.190058.107","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S2213-2600(16)30222-3","article-title":"Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities","volume":"5","author":"King","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2024102403404831000_28.153.190058.108","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1016\/j.jtho.2017.03.008","article-title":"A case of a patient with idiopathic pulmonary fibrosis with lung squamous cell carcinoma treated with nivolumab","volume":"12","author":"Khunger","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.rmr.2018.11.001","article-title":"Le nivolumab peut-il \u00eatre utilis\u00e9 dans les fibroses pulmonaires idiopathiques? [Can nivolumab be used safely in idiopathic pulmonary fibrosis?]","volume":"36","author":"Duchemann","year":"2019","journal-title":"Rev Mal Respir"},{"key":"2024102403404831000_28.153.190058.110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"2024102403404831000_28.153.190058.111","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"2024102403404831000_28.153.190058.112","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.3298"},{"key":"2024102403404831000_28.153.190058.113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9693"},{"key":"2024102403404831000_28.153.190058.114","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"5","author":"Wilgenhof","year":"2012","journal-title":"Anticancer Res"},{"key":"2024102403404831000_28.153.190058.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.028"},{"key":"2024102403404831000_28.153.190058.116","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"2024102403404831000_28.153.190058.117","doi-asserted-by":"publisher","DOI":"10.1159\/000161122"},{"key":"2024102403404831000_28.153.190058.118","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00107912"},{"key":"2024102403404831000_28.153.190058.119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors \u2013 an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2024102403404831000_28.153.190058.120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2024102403404831000_28.153.190058.121","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.rmr.2018.08.003","article-title":"Granulomatose sarco\u00efdosique survenant sous inhibiteurs de point de contr\u00f4le immunitaire. [Sarcoud-like granulomatosis in cancer patients treated with immune checkpoint inhibitors]","volume":"35","author":"Faviez","year":"2018","journal-title":"Rev Mal Respir"},{"key":"2024102403404831000_28.153.190058.122","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2015.10.082"},{"key":"2024102403404831000_28.153.190058.123","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/bjd.14808","article-title":"Pulmonary sarcoid-like granulomatosis induced by nivolumab","volume":"176","author":"Montaudi\u00e9","year":"2017","journal-title":"Br J Dermatol"},{"key":"2024102403404831000_28.153.190058.124","first-page":"126","article-title":"Pembrolizumab reactivates pulmonary granulomatosis","volume":"22","author":"Al-dliw","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"2024102403404831000_28.153.190058.125","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000480155","article-title":"EBUS-TBNA can distinguish sarcoid-like side effect of nivolumab treatment from tumor progression in non-small cell lung cancer","volume":"94","author":"Lainez","year":"2017","journal-title":"Respiration"},{"key":"2024102403404831000_28.153.190058.126","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1159\/000492383","article-title":"Sarcoid-like granulomatosis induced by nivolumab treatment in a lung cancer patient","volume":"11","author":"Noguchi","year":"2018","journal-title":"Case Rep Oncol"},{"key":"2024102403404831000_28.153.190058.127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2569"},{"key":"2024102403404831000_28.153.190058.128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/imt-2018-0035","article-title":"Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma","volume":"10","author":"Mitchell","year":"2018","journal-title":"Immunotherapy"},{"key":"2024102403404831000_28.153.190058.129","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14-1475"},{"key":"2024102403404831000_28.153.190058.130","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201503-0635LE","article-title":"Decreased cytotoxic T-lymphocyte antigen 4 expression on regulatory T cells and Th17 cells in sarcoidosis: double trouble?","volume":"192","author":"Broos","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403404831000_28.153.190058.131","unstructured":"Bristol-Meyers Squibb Pharmaceutical Research Institute . Effect of MDX-1106 on CD4+ T Cells During an Allogeneic Mixed Lymphocyte Reaction (MLR) (Medarex Study No. MDX-1106-026-R). Document Control no. 930046581. 2006."},{"key":"2024102403404831000_28.153.190058.132","first-page":"928601","article-title":"Sarcoidosis: immunopathogenesis and immunological markers","volume":"2013","author":"Loke","year":"2013","journal-title":"Int J Chronic Dis"},{"key":"2024102403404831000_28.153.190058.133","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.10.2104046"},{"key":"2024102403404831000_28.153.190058.134","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262207"},{"key":"2024102403404831000_28.153.190058.135","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cmi.2017.12.003","article-title":"Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment","volume":"24","author":"Picchi","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2024102403404831000_28.153.190058.136","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jtho.2016.07.006","article-title":"Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis","volume":"11","author":"Fujita","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.137","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2017.03.012","article-title":"Pericardial tamponade caused by a hypersensitivity response to tuberculosis reactivation after Anti-PD-1 treatment in a patient with advanced pulmonary adenocarcinoma","volume":"12","author":"Chu","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2024102403404831000_28.153.190058.138","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jiac.2018.06.016","article-title":"Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents","volume":"25","author":"Takata","year":"2019","journal-title":"J Infect Chemother"},{"key":"2024102403404831000_28.153.190058.139","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.2147\/OTT.S178246","article-title":"Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report","volume":"11","author":"He","year":"2018","journal-title":"OncoTargets Ther"},{"key":"2024102403404831000_28.153.190058.140","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat2702"},{"key":"2024102403404831000_28.153.190058.141","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/0284186X.2015.1125017","article-title":"Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma","volume":"55","author":"Lee","year":"2016","journal-title":"Acta Oncol"},{"key":"2024102403404831000_28.153.190058.142","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-015-0532-2"},{"key":"2024102403404831000_28.153.190058.143","doi-asserted-by":"publisher","DOI":"10.1007\/s003300050989"},{"key":"2024102403404831000_28.153.190058.144","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw539"},{"key":"2024102403404831000_28.153.190058.145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.rmed.2018.11.021","article-title":"Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy","volume":"146","author":"Fujita","year":"2019","journal-title":"Respir Med"},{"key":"2024102403404831000_28.153.190058.146","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"2024102403404831000_28.153.190058.147","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"2024102403404831000_28.153.190058.148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901"},{"key":"2024102403404831000_28.153.190058.149","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414428"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0058-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:01:12Z","timestamp":1740355272000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0058-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":149,"journal-issue":{"issue":"153","published-online":{"date-parts":[[2019,10,9]]},"published-print":{"date-parts":[[2019,9,30]]}},"alternative-id":["10.1183\/16000617.0058-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0058-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,30]]}}}